Iclusig 15 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Ponatinib, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 30 mg film-coated tablets., Ponatinib, Iclusig 45 mg film-coated tablets, Ponatinib
INCB 84344-102
Phase 2 small_molecule active
Quick answer
Iclusig 15 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Ponatinib, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 30 mg film-coated tablets., Ponatinib, Iclusig 45 mg film-coated tablets, Ponatinib for Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors is a Phase 2 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active